[ad_1]
After the UK granted emergency use approval for the Covid-19 vaccine jointly developed by Pfizer and BioNTech, approval studies for vaccines developed by pharmaceutical companies in China gained momentum. Chinese Vice Premier Sun Chunlan visited Sinovac and Sinopharm companies on Wednesday, which led the race to develop the Covid-19 vaccine with the National Food and Drug Control Administration. After inspecting the two companies’ production lines, Chunlan asked that the companies be ready for large-scale vaccine production.
Chinese state media evaluated Chunlan’s visits to State Council member Wang Yong as a sign that the launch of the Covid-19 vaccine in China is approaching. Chinese experts announced that the country plans to approve the use of 600 million doses of the vaccine by the end of the year. The massive use of vaccines in China is expected to be officially approved in December, but uncertainties remain about the scope, scale and price of the vaccines.
THE COMPANIES DO NOT DISCLOSE THE DATA OF THE LAST STAGE
Chinese companies have yet to provide data on the tests, although they have indicated that the vaccine trials are in their final stages. The emergency use of the Sinopharm and Sinovac vaccines was approved before the clinical trials were completed.
Yin Weidong, Sinovac’s chief executive, said in September that between 97 and 98 percent of the volunteers developed antibodies. It was indicated that the company increased its capacity to produce 300 million doses of vaccine annually.
Pfizer-BioNTech reported that the latest testing of the vaccine it developed showed the vaccine was 95 percent effective in patients. It is claimed that it is difficult for the World Health Organization (WHO) to issue an emergency use license unless convincing data on the effect and safety of the vaccines are provided.
